ImmunoGen (IMGN) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

License and milestone fees
05M10M15M20M25M30M35M40MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
050M100M150M200M250M300M350M400MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

EBITDA

EBITDA
-90M-74M-58M-41M-25M-9M8M24M40MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

EPS

EPSEPS Diluted
000001111Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Revenue Variation (%)

Revenue Variation
0255075100125150175200Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
03875112150188225262300Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Revenue YoY Variation (%)

Revenue YoY Variation
0100200300400500600700800Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0100200300400500600700800Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Price-to-Earning Ratio

P/E Ratio
-400-344-288-231-175-119-62-650Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
02505007501K1K2K2K2KQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
010M20M30M40M50M60M70M80MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
011223445Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0625K1M2M2M3M4M4M5MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023

Cash Flow to Debt Ratio

Cash At End Of Period
088M175M262M350M438M525M612M700MQ3 2022Q4 2022Q1 2023Q2 2023Q3 2023
🏦 Balance Sheet
📈 Key Metrics